{"id":577,"date":"2014-07-11T12:21:17","date_gmt":"2014-07-11T16:21:17","guid":{"rendered":"http:\/\/allphasepharma.com\/dir\/?p=577"},"modified":"2014-08-31T16:14:24","modified_gmt":"2014-08-31T20:14:24","slug":"bacterial-vaccine-targets","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2014\/07\/11\/577\/bacterial-vaccine-targets\/","title":{"rendered":"Bacterial Vaccine Targets"},"content":{"rendered":"

A recent publication [1] from the team which brought us the Meningococcal B vaccine is of interest from the perspective of vaccine development strategy and feasibility.\u00a0<\/p>\n

\"Bacterial<\/a>
Bacterial Vaccine Targets<\/figcaption><\/figure>\n

Appropriately, tuberculosis (TB) leads the list of important bacterial targets for vaccine research. Despite numerous attempts, all the vaccines candidate tested so far had insufficient efficacy in clinical trials.\u00a0 Many parts of the world still have to rely on the immune stimulation provided by the old BCG vaccine which \u2013 by the way \u2013 provides incomplete protection and can have significant local and systemic side effects.<\/p>\n

The authors summarize the disappointing experience with so many S. aureus vaccines which turned out to be failures. It seems that opsonizing antibodies are just not sufficient to prevent disease; T-cell mediated immunity is probably much more important for controlling this pathogen than previously considered [2].\u00a0 Several antibody-based approaches were unsuccessful, including a recent trial with the V710 vaccine directed against IsdB.<\/p>\n

Travelers are exposed to many illnesses for which vaccines are either not available or not very effective.\u00a0 There is a growing need for protection against Shigella and ETEC, both toxin-mediated diseases which have many similarities.\u00a0 Clearly, the efficacy of the existing Cholera vaccine is suboptimal.<\/p>\n

Although not discussed in the article, an accompanying table shows that the researchers also have vaccines directed against Klebsiella and Pseudomonas on their radar.\u00a0 A Pseudomonas vaccine is in Phase 2 at Novartis, in collaboration with Intercell.\u00a0 This is the partnership that brought us a vaccine for Japanese encephalitis (Ixiaro) a few years ago.<\/p>\n

There is also a joint effort with Intercell to work on a vaccine against C. difficile.\u00a0 This nicely complements the in-house LFF-571 program, a novel MoA compound (elongation factor inhibitor) which seems to have finished Phase 2 testing.\u00a0 Somewhat surprisingly, the compound is not included in the Novartis drug pipeline chart [3] .\u00a0 Probably just an oversight\u2026<\/p>\n

\n

References:\u00a0<\/strong><\/p>\n

[1] Delany. Vaccines for the 21st century EMBO Mol Med. 2014; 6:708
\n[2] Joshi.\u00a0 Developing a universal S. aureus vaccine: Why aren\u2019t we there yet?\u00a0 Intern. Med. 2013; 3: 2
\n[3] http:\/\/www.novartis.com\/innovation\/research-development\/clinical-pipeline\/index.shtml<\/p>\n","protected":false},"excerpt":{"rendered":"

A recent publication [1] from the team which brought us the Meningococcal B vaccine is of interest from the perspective of vaccine development strategy and feasibility.\u00a0<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[227],"tags":[403,412,306,76,408,409,305,407,303,302,413,414,296,304,174,405,196,410,299,406,294,404,411],"class_list":["post-577","post","type-post","status-publish","format-standard","hentry","category-recent_literature","tag-antibiotic-blog","tag-bacterial-vaccine-targets","tag-bcg-vaccine","tag-c-difficile","tag-cholera-vaccine","tag-ef-tu","tag-elongation-factor","tag-etec","tag-gas","tag-gbs","tag-group-a-streptococcus","tag-group-b-streptococcus","tag-klebsiella","tag-lff-571","tag-novartis","tag-opsonizing-antibodies","tag-pseudomonas","tag-s-aureus-vaccine","tag-shigella","tag-t-cell-immunity","tag-tb","tag-tuberculosis","tag-v710-vaccine"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-9j","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":671,"url":"https:\/\/allphasepharma.com\/dir\/2014\/08\/02\/671\/learning-from-set-backs-the-frustrating-search-for-a-staphylococcal-vaccine\/","url_meta":{"origin":577,"position":0},"title":"Learning from Set-Backs: The Frustrating Search for a Staphylococcal Vaccine","author":"Harald","date":"August 2, 2014","format":false,"excerpt":"Several reasons have been proposed as explanations why so many\u00a0S. aureus vaccines\u00a0have failed in clinical trials.\u00a0 Clearly, the organism has a battery of virulence factors which may require a multipronged approach and\u00a0neutralizing just a single mechanism with a specific mAb may not suffice. However, passive immunization with polyclonal antibodies did\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"IgG antibody","src":"http:\/\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/08\/antibody.jpe","width":350,"height":200},"classes":[]},{"id":1470,"url":"https:\/\/allphasepharma.com\/dir\/2015\/05\/21\/1470\/vaccine-mismatch-the-influenza-season-2014-2015\/","url_meta":{"origin":577,"position":1},"title":"Vaccine Mismatch \u2013 The Influenza Season 2014 \/ 2015","author":"Harald","date":"May 21, 2015","format":false,"excerpt":"PLEASE SHARE YOUR OPINION AND VOTE\u00a0BELOW \u00a0 It has\u00a0always been a bit of a gamble: Predicting the main circulating flu types and subtypes for the next season based on information from the previous season is an educated guess. \u00a0It works well most of the time but fails when there is\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"2003 Vaccine Effectiveness","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/05\/2003-Vaccine-Effectiveness.jpg?resize=350%2C200","width":350,"height":200},"classes":[]},{"id":2596,"url":"https:\/\/allphasepharma.com\/dir\/2016\/07\/07\/2596\/is-laiv-dead-or-just-on-laiv-support\/","url_meta":{"origin":577,"position":2},"title":"Is LAIV Dead or Just on LAIV-Support?","author":"Harald","date":"July 7, 2016","format":false,"excerpt":"Very recently we came across several studies in which small differences in design\u00a0had a major\u00a0impact on outcomes. A blog\u00a0is not a good\u00a0place\u00a0to dig deeply into the minutiae of study design as the discussion\u00a0becomes quickly very dry and quite\u00a0technical. However, readers and clinicians are often unaware how a seemingly small change\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"VE slider","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/07\/VE-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/07\/VE-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/07\/VE-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":5948,"url":"https:\/\/allphasepharma.com\/dir\/2025\/12\/15\/5948\/influenza-vaccination-in-the-elderly\/","url_meta":{"origin":577,"position":3},"title":"INFLUENZA VACCINATION IN THE ELDERLY","author":"Harald","date":"December 15, 2025","format":false,"excerpt":"In 2024, the ECDC published a detailed review of flu vaccine studies [1].\u00a0 In particular, the report examined published trials of newer flu vaccines.\u00a0 As is well known, the older vaccines provide significant protection, but efficacy is diminished in certain populations.\u00a0 Especially the elderly are at an increased risk of\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/12\/image.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/12\/image.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/12\/image.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/12\/image.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/12\/image.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/12\/image.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":1840,"url":"https:\/\/allphasepharma.com\/dir\/2015\/08\/06\/1840\/the-etiology-of-cap-remains-elusive-a-call-to-change-antibiotic-prescribing-patterns\/","url_meta":{"origin":577,"position":4},"title":"The Etiology of CAP Remains Elusive \u2013 A Call to Change Antibiotic Prescribing Patterns","author":"Harald","date":"August 6, 2015","format":false,"excerpt":"Once upon\u00a0a time - not so long ago -\u00a0we were taught the following: Streptococcus pneumoniae was the cause of 90% of CAP cases. That statement was later modified to mean S. pneumoniae was the underlying pathogen in 90% of bacterial\u00a0cases of CAP, i.e., those with positive cultures from sputum or\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"CAP slider 2","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/08\/CAP-slider-2.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/08\/CAP-slider-2.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/08\/CAP-slider-2.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":5533,"url":"https:\/\/allphasepharma.com\/dir\/2025\/10\/09\/5533\/about-diphtheria\/","url_meta":{"origin":577,"position":5},"title":"About DIPHTHERIA","author":"Harald","date":"October 9, 2025","format":false,"excerpt":"The early work on the organism and the toxoid vaccine reads like the \u2018Who Is Who\u2019 of microbiology: Klebs, Loeffler, Koch, Roux, Yersin, Behring, Kitasato, Schick, and T. Smith were all involved in bringing this deadly disease under control. In those days bacteria and diseases were referred to by the\u2026","rel":"","context":"In "Did you know...?"","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/10\/Diphtheria-SLIDER.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/10\/Diphtheria-SLIDER.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/10\/Diphtheria-SLIDER.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/577","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=577"}],"version-history":[{"count":12,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/577\/revisions"}],"predecessor-version":[{"id":808,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/577\/revisions\/808"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=577"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=577"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=577"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}